The agreement gives Novartis options to secure exclusive rights to develop and commercialise multiple subcutaneous products using Alteogen's ALT-B4 Hybrozyme technology. Alteogen has entered into an option and licence agreement with Novartis covering the development and commercialisation of subcutaneous formulations of multiple Novartis products using ALT-B4. The deal further expands the global reach of Alteogen's Hybrozyme platform, which uses recombinant human hyaluronidase technology to enable medicines currently administered intravenously to be reformulated for subcutaneous delivery. Field Content Alert Type Deal Companies Alteogen; Novartis Deal Type Option and licence agreement Asset or Company ALT-B4 / Hybrozyme technology Therapy Area(s) Multiple therapeutic areas Technology or Modality Recombinant human hyaluronidase drug-delivery platform Deal Value Financial terms were not disclosed Geography Global What Happened Novartis obtained multiple options to secure exclusive rights to develop and commercialise subcutaneous formulations of multiple products using Alteogen's ALT-B4 Hybrozyme technology. Why It Matters The agreement extends adoption of Alteogen's drug-delivery platform by another major pharmaceutical company and could enable more convenient subcutaneous versions of existing biologic medicines. Supporting Context ALT-B4, or berahyaluronidase alfa, is a recombinant human hyaluronidase designed to facilitate conversion of intravenous biologic medicines into subcutaneous formulations. Strategic Rationale Novartis gains access to a platform that can support more convenient administration of multiple medicines while Alteogen expands the commercial reach of Hybrozyme. Potential Impact Successful development could reduce administration time and improve treatment convenience for products selected under the agreement. Key Takeaway Novartis has secured options to use Alteogen's ALT-B4 platform across multiple subcutaneous product programmes. What to Watch Which Novartis products are selected under the options and subsequent development of ALT-B4-enabled subcutaneous formulations. Primary Source Alteogen Relevant Date 2 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The agreement gives GSK worldwide rights outside Greater China to develop and commercialise HUTCHMED's first-in-class KRAS-EGFR antibody-targeted therapy conjugate HMPL-A830. HUTCHMED will receive $110 million upfront and is eligible for a further $1.185 billion in development, regulatory and commercial milestones, taking the potential deal value to $1.295 billion, plus tiered royalties. HMPL-A830 is expected to enter clinical development in the second half of 2026, initially targeting colorectal, pancreatic and lung cancers with KRAS alterations. Field Content Alert Type Deal Companies GSK; HUTCHMED Deal Type Exclusive development and licence agreement Asset or Company HMPL-A830 Therapy Area(s) Oncology; colorectal cancer; pancreatic cancer; lung cancer Technology or Modality KRAS-EGFR antibody-targeted therapy conjugate Deal Value Up to $1.295 billion, including $110 million upfront and up to $1.185 billion in development, regulatory and commercial milestone payments, plus tiered royalties Development Stage Preclinical / preparing for Phase I clinical development Geography Worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan What Happened GSK secured exclusive development and commercialisation rights outside Greater China to HUTCHMED's HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate. Why It Matters The transaction gives GSK access to a novel precision-oncology platform designed to deliver a KRAS inhibitor directly to EGFR-expressing tumours while simultaneously blocking EGFR and KRAS signalling. Supporting Context HUTCHMED expects global Phase I development of HMPL-A830 to begin in the second half of 2026, initially focusing on colorectal, pancreatic and lung cancers. Strategic Rationale GSK gains a differentiated KRAS-targeted oncology candidate while HUTCHMED retains development and commercialisation rights in Greater China. Potential Impact If successful, HMPL-A830 could provide a new targeted approach for patients with KRAS-altered tumours that remain difficult to treat with existing therapies. Key Takeaway GSK is committing up to $1.295 billion for ex-Greater China rights to HUTCHMED's novel KRAS-EGFR oncology candidate HMPL-A830. What to Watch Initiation of the global Phase I programme and early clinical evidence for HMPL-A830 in KRAS-altered solid tumours. Primary Source HUTCHMED Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Samsung Bioepis has received Japanese marketing approval for a 130mg intravenous formulation of its ustekinumab biosimilar referencing Stelara. The newly approved intravenous formulation is indicated as induction therapy for patients with moderate-to-severe active Crohn's disease where other treatments are ineffective. The approval is Samsung Bioepis' second Japanese ustekinumab biosimilar approval through its partnership with NIPRO, following the previously approved 45mg subcutaneous syringe formulation. Field Content Alert Type Approval Drug Name Ustekinumab biosimilar Brand Name Ustekinumab BS Intravenous Infusion 130mg NIPRO Company Samsung Bioepis; NIPRO Corporation Reference Product Stelara Regulatory Authority Japanese regulatory authorities Approval Type Marketing approval Indication Induction therapy for moderate-to-severe active Crohn's disease where other treatments are ineffective Therapy Area(s) Gastroenterology; inflammatory bowel disease Geography Japan What Happened Samsung Bioepis received Japanese marketing approval for the 130mg intravenous formulation of its ustekinumab biosimilar referencing Stelara. Why It Matters The approval expands the available formulations of Samsung Bioepis' ustekinumab biosimilar in Japan and provides an intravenous induction option for eligible Crohn's disease patients. Supporting Context The approval follows the earlier Japanese approval of the 45mg subcutaneous syringe formulation through Samsung Bioepis' partnership with NIPRO Corporation. Key Takeaway Samsung Bioepis has expanded its Japanese ustekinumab biosimilar offering with approval of a 130mg intravenous induction formulation. What to Watch Commercial rollout through NIPRO and adoption of the intravenous biosimilar in Japanese Crohn's disease treatment. Primary Source Samsung Bioepis Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved Zanvastro as the first treatment for Alexander disease in paediatric and adult patients. Zanvastro, also known as zilganersen, is the first FDA-approved therapy for Alexander disease and the first treatment designed to directly address the GFAP protein accumulation that drives the rare neurological disorder. The approval introduces a disease-targeted treatment for patients who previously had no approved therapeutic option beyond supportive care. Field Content Alert Type Approval Drug Name Zilganersen Brand Name Zanvastro Company Ionis Pharmaceuticals Regulatory Authority U.S. Food and Drug Administration Approval Type New drug approval Indication Treatment of Alexander disease in paediatric and adult patients Therapy Area(s) Neurology; rare disease Geography United States What Happened The FDA approved Zanvastro (zilganersen) for the treatment of Alexander disease in paediatric and adult patients. Why It Matters Zanvastro is the first FDA-approved treatment for Alexander disease and the first therapy designed to directly target the underlying protein accumulation driving the disorder. Supporting Context Alexander disease is a rare progressive neurological disorder caused by mutations affecting glial fibrillary acidic protein, or GFAP. Key Takeaway FDA approval of Zanvastro establishes the first disease-targeted treatment option for people with Alexander disease. What to Watch Clinical adoption of Zanvastro and longer-term evidence on its impact across paediatric and adult Alexander disease populations. Primary Source U.S. Food and Drug Administration Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

ADCAN Pharma and Pinnacle Life Science have entered into a licensing and technology-transfer partnership covering 12 oncology products and their planned local manufacture in the UAE. The agreement combines product licensing with staged technology transfer intended to build local manufacturing capability for critical oncology medicines. The partnership supports pharmaceutical localisation in the UAE while expanding ADCAN Pharma's oncology manufacturing portfolio. Field Content Alert Type Deal Companies ADCAN Pharma; Pinnacle Life Science Deal Type Licensing and technology-transfer agreement Assets 12 oncology products Therapy Area(s) Oncology Geography United Arab Emirates Deal Value Financial terms were not disclosed What Happened ADCAN Pharma and Pinnacle Life Science entered into an agreement covering the licensing of 12 oncology products and staged transfer of manufacturing technology to the UAE. Why It Matters The partnership expands local access to oncology products while supporting the development of domestic pharmaceutical manufacturing capacity. Strategic Rationale ADCAN gains access to a broader oncology portfolio and manufacturing know-how, while Pinnacle extends its products into the UAE market through a local partner. Potential Impact Successful technology transfer could increase local production of oncology medicines and reduce dependence on imported supply. Key Takeaway The agreement combines licensing of 12 oncology products with a structured programme to transfer manufacturing capability into the UAE. What to Watch Completion of the technology-transfer stages, regulatory approvals and commencement of local manufacture. Primary Source ADCAN Pharma Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

TScan Therapeutics is cutting approximately 75% of its workforce and pausing further enrolment in its Phase 3 ALLOHA-2 study as it redirects resources towards in vivo cell therapy programmes for solid tumours. The restructuring reflects a major strategic shift driven by capital constraints, with TScan prioritising development of its solid-tumour TCR-T programmes. The company is substantially reducing operating costs while concentrating its remaining resources on programmes it believes offer the strongest future development potential. Field Content Alert Type Industry Update Company TScan Therapeutics Update Type Strategic restructuring and workforce reduction Workforce Impact Approximately 75% workforce reduction Programme Impact Further enrolment in the Phase 3 ALLOHA-2 study paused Therapy Area(s) Oncology; solid tumours Technology or Modality TCR-T cell therapy; in vivo cell therapy What Happened TScan Therapeutics announced a strategic reorganisation involving a workforce reduction of approximately 75% and a pause in further enrolment in the Phase 3 ALLOHA-2 programme. Why It Matters The scale of the restructuring materially changes TScan's development strategy and reflects the financial pressures facing clinical-stage biotechnology companies. Strategic Focus Resources will be redirected towards in vivo cell therapy programmes for solid tumours. Supporting Context The company cited capital constraints as a key factor behind the decision to pause further ALLOHA-2 enrolment and reduce its cost base. Potential Impact The restructuring extends resources towards selected pipeline priorities but significantly reduces the company's near-term development footprint. Key Takeaway TScan is making a major strategic pivot towards in vivo solid-tumour cell therapy while cutting approximately three-quarters of its workforce. What to Watch Progress of TScan's in vivo solid-tumour programmes and any further changes to the ALLOHA-2 programme. Primary Source TScan Therapeutics Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Interventional radiology and neurosurgery recorded the largest year-on-year physician compensation increases in Doximity's 2026 compensation analysis. Interventional radiology compensation increased by 10.8%, while neurosurgery rose by 10.7%, placing the two specialties at the top of the annual pay-growth rankings. The findings come from Doximity's 2026 Physician Compensation Report, which draws on compensation data from more than 23,000 physicians. Field Content Alert Type Compensation Report Doximity 2026 Physician Compensation Report Topic Physician specialty compensation growth Top Specialty Interventional radiology Interventional Radiology Pay Growth 10.8% year-on-year Second Specialty Neurosurgery Neurosurgery Pay Growth 10.7% year-on-year Sample Size More than 23,000 physicians What Happened Doximity's 2026 compensation analysis identified interventional radiology and neurosurgery as the physician specialties with the largest year-on-year increases in compensation. Why It Matters The figures highlight where physician earnings are rising fastest and provide an indicator of shifting demand, labour-market pressure and specialty economics. Supporting Context The analysis is based on physician compensation data collected for Doximity's 2026 Physician Compensation Report. Key Takeaway Interventional radiology and neurosurgery led physician specialty pay growth in 2026, with increases of 10.8% and 10.7% respectively. What to Watch Whether these growth rates persist and how compensation trends vary by geography, employment model and specialty demand. Primary Source Becker's ASC / Doximity Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Biocytogen has granted Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody from its RenNano platform for the development of neuroscience therapies. The agreement gives Qilu access to a Biocytogen antibody asset while allowing Biocytogen to continue licensing the platform and related assets to other partners. Financial terms and the specific therapeutic target were not disclosed, but the transaction adds another external development partnership around Biocytogen's antibody discovery technology. Field Content Alert Type Deal Companies Biocytogen; Qilu Pharmaceutical Deal Type Non-exclusive licensing agreement Asset or Company Fully human VHH antibody Platform RenNano Therapy Area(s) Neuroscience Technology or Modality Fully human VHH antibody Deal Value Financial terms were not disclosed What Happened Biocytogen granted Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody generated using its RenNano platform for use in neuroscience drug development. Why It Matters The transaction extends commercial use of Biocytogen's antibody discovery platform and gives Qilu access to a potentially differentiated antibody asset for neuroscience research. Supporting Context The specific therapeutic target and detailed development programme were not disclosed. Strategic Rationale The non-exclusive structure allows Biocytogen to monetise its platform while retaining the ability to pursue additional partnerships. Potential Impact The agreement may support development of new antibody-based treatments for neurological conditions if Qilu advances the programme successfully. Key Takeaway Biocytogen has licensed a RenNano-derived fully human VHH antibody to Qilu for neuroscience development under a non-exclusive agreement. What to Watch Disclosure of the target, development programme and any subsequent clinical progression. Primary Source Biocytogen / Qilu Pharmaceutical Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Qualcomm and ASUS have launched an on-premises AI assistant programme for community pharmacies across southern Taiwan. The initiative is designed to support medication safety, drug-interaction detection and pharmacy workflow efficiency using locally deployed artificial intelligence technology. The programme represents a practical healthcare deployment of generative AI infrastructure rather than a general technology demonstration. Field Content Alert Type Industry Update Companies Qualcomm; ASUS Update Type Healthcare AI deployment Sector Community pharmacy Technology On-premises AI assistant Use Cases Medication safety; drug-interaction detection; pharmacy workflow support Geography Southern Taiwan What Happened Qualcomm and ASUS launched an AI assistant programme for community pharmacies in southern Taiwan using on-premises computing infrastructure. Why It Matters The initiative demonstrates how generative AI tools are moving into frontline pharmacy workflows where privacy, local processing and medication-safety applications are particularly important. Supporting Context The system is intended to assist pharmacists with medication information, drug-interaction checks and operational workflows. Strategic Rationale On-premises deployment can support healthcare organisations that require greater control over sensitive data and system performance. Potential Impact Successful deployment could improve pharmacy efficiency and support safer medication management while providing a model for wider healthcare AI adoption. Key Takeaway Qualcomm and ASUS are deploying an on-premises AI assistant across community pharmacies in southern Taiwan to support medication safety and pharmacy operations. What to Watch Expansion of the programme, pharmacist adoption and evidence of improvements in workflow efficiency or medication safety. Primary Source ASUS Relevant Date 3 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

ArsenalBio is cutting 99 jobs as it restructures the company around a strategic shift towards in vivo CAR-T development. The reduction represents the majority of ArsenalBio's workforce and concentrates resources on a smaller core team focused on its new in vivo cell-therapy strategy. The restructuring marks a significant change from the company's previous development model and reflects growing industry interest in CAR-T therapies that can potentially be generated directly inside patients. Field Content Alert Type Industry Update Company ArsenalBio Update Type Restructuring and R&D strategy shift Jobs Affected 99 employees Strategic Focus In vivo CAR-T development Therapy Area Oncology; cell therapy Technology or Modality CAR-T cell therapy Geography United States What Happened ArsenalBio is eliminating 99 positions as part of a restructuring that shifts the company's development focus towards in vivo CAR-T therapies. Why It Matters The workforce reduction and strategic pivot represent a material change in ArsenalBio's R&D model and technology priorities. Strategic Rationale A smaller core team will focus resources on development of the company's in vivo CAR-T strategy. Potential Impact The restructuring could substantially alter ArsenalBio's pipeline, workforce requirements and future financing needs. Key Takeaway ArsenalBio is cutting most of its workforce and repositioning the company around in vivo CAR-T development. What to Watch Details of the in vivo CAR-T pipeline and the future of ArsenalBio's existing programmes. Primary Source BioSpace Relevant Date 1 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

BeOne Medicines has reached a voluntary agreement with the US government covering cancer medicine access, future pricing and continued investment in US pharmaceutical manufacturing. BeOne has joined the US government's GENEROUS pricing model and committed to internationally aligned pricing for future FDA-approved medicines. The company has also secured a Section 232 pharmaceutical tariff exemption linked to its US manufacturing investment, connecting medicine pricing, market access and domestic production strategy. Field Content Alert Type Industry Update Company BeOne Medicines Agreement Type US government pricing and access agreement Sector Oncology; pharmaceutical pricing; manufacturing Programme GENEROUS pricing model Geography United States What Happened BeOne Medicines announced a voluntary agreement with the US government covering medicine access, future pharmaceutical pricing and continued investment in domestic manufacturing. Pricing Commitment BeOne joined the GENEROUS pricing model and committed to internationally aligned pricing for future FDA-approved medicines. Tariff Treatment The company secured a Section 232 pharmaceutical tariff exemption linked to its US manufacturing investment. Why It Matters The agreement connects pharmaceutical pricing, patient access and domestic manufacturing policy in a way that could influence commercial strategy for oncology medicines in the United States. Potential Impact The commitments could affect future launch pricing, Medicaid access and BeOne's US manufacturing economics. Key Takeaway BeOne has combined US pricing commitments with domestic manufacturing investment and a pharmaceutical tariff exemption. What to Watch Implementation of the pricing commitments and further expansion of BeOne's US manufacturing footprint. Primary Source BeOne Medicines Relevant Date 1 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Novacyt and Illumina have entered into a five-year master collaboration agreement to explore molecular-diagnostics product development and commercial opportunities. The agreement creates a framework for the companies to combine Novacyt's molecular-diagnostics capabilities with Illumina's sequencing and array technologies across potential future projects. The collaboration is an enabling framework rather than a commitment to a single product programme, with individual projects expected to require separate agreements. Field Content Alert Type Industry Update Companies Novacyt; Illumina Agreement Type Master collaboration agreement Agreement Term Five years Sector Molecular diagnostics; genomics Technology or Modality Molecular diagnostics, DNA sequencing and array technologies Geography Global What Happened Novacyt and Illumina entered into a five-year master collaboration agreement to explore future product-development and commercial opportunities. Why It Matters The framework links Novacyt's molecular-diagnostics capabilities with Illumina's sequencing and array technologies. Supporting Context Specific projects arising from the framework are expected to be governed by separate agreements. Potential Impact Successful projects could broaden Novacyt's diagnostic-development capabilities and create new applications using Illumina technologies. Key Takeaway Novacyt and Illumina have established a five-year framework for potential molecular-diagnostics collaboration. What to Watch Announcement of specific projects or commercial programmes under the collaboration. Primary Source Novacyt Relevant Date 1 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com